ETNB

89bio
ETNB

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.44B
EV
$838.20M
Shares Outstanding
157.32M
Beta
1.52

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$29.45
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About 89bio, Inc.

gainify
ETNB

89bio, Inc.

ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth fa...

Sector

Healthcare

Industry

Biotechnology

CEO

Palekar, Rohan

Employees

93

IPO Date

2019-11-11

Headquarters

142 Sansome Street, Second Floor, San Francisco, California, 94104, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.